Scarica l'app Stockscreener
65.63
3.88%
-2.65
Dopo l'orario di chiusura:
65.25
-0.38
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed: Q1 Earnings Snapshot - MySA
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches - Investing.com
Insmed earnings missed by $0.07, revenue topped estimates - Investing.com
Insmed Inc (INSM) Q1 2025 Earnings: Revenue Hits $92.8 Million, Surpassing Estimates - GuruFocus
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update | INSM Stock News - GuruFocus
Insmed Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Dimensional Fund Advisors LP Sells 16,313 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy - Insider Monkey
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline - Yahoo Finance
Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential - Insider Monkey
Insmed To Present at the BofA Securities 2025 Health Care Conference - GuruFocus
Insmed To Present at the BofA Securities 2025 Health Care Conference | INSM Stock News - GuruFocus
Insmed to Reveal Latest Updates at Major BofA Healthcare Conference This May - Stock Titan
Insmed Inc (INSM)’s Day in Review: Closing at 69.69, Up by 1.06 - DWinneX
Gaining Ground: Insmed Inc (INSM) Closes Lower at 72.00, Down -5.62 - DWinneX
Top Medical Stocks To Watch Now – April 25th - Defense World
Insmed Inc [INSM] moved down -2.60: Why It’s Important - dbtnews.com
Could investigational drug become first-in-class bronchiectasis therapy? - marketscreener.com
Insmed: Poised For Transformation Beyond ARIKAYCE (NASDAQ:INSM) - Seeking Alpha
Insmed Inc [INSM] stock for 479,177 USD was sold by Lewis William - knoxdaily.com
Insmed’s (INSM) Buy Rating Reiterated at HC Wainwright - Defense World
Insmed Sees Unusually Large Options Volume (NASDAQ:INSM) - Defense World
Insmed Inc (INSM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Insmed Calls In Convertible Notes, Proposes Share Conversion - Finimize
Insmed to redeem $569.5 million convertible notes due 2028 By Investing.com - Investing.com Canada
Insmed Inc (NASDAQ:INSM) Rises 5.71% In 2025; Is It Still Attractive At $70.85? - Marketing Sentinel
INSM’s price-to-sales ratio: A comparative analysis with its peers - uspostnews.com
Insmed to Redeem $569.5 Million of Convertible Senior Notes - marketscreener.com
Insmed Announces Redemption of all $569.5 Million of Remaining O - GuruFocus
Insmed Flexes Financial Muscle with $569M Early Note Redemption: What it Means for Investors - Stock Titan
Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis | INSM Stock News - GuruFocus
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib in Treating Bronchiectasis | INSM Stock News - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - marketscreener.com
Insmed to Host First-Quarter 2025 Financial Results Conference C - GuruFocus
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 | INSM Stock News - GuruFocus
Insmed Q1 2025 Earnings Preview: What New Financial Metrics Will Shape Growth Strategy? - Stock Titan
H.C. Wainwright maintains Buy on Insmed stock with $90 target By Investing.com - Investing.com Canada
Cerity Partners LLC Sells 3,090 Shares of Insmed Incorporated (NASDAQ:INSM) - American Banking and Market News
Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Analysts - Defense World
Insmed CEO William Lewis sells $479,176 in stock By Investing.com - Investing.com Canada
Insmed’s Chief Commercial Officer Resigns for Personal Reasons - TipRanks
Insmed CEO William Lewis sells $479,176 in stock - Investing.com Australia
New cathepsin C inhibitors disclosed in Insmed patent - BioWorld MedTech
5.73%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):